Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation
Which stocks are undervalued right now? Check free
Discover now →
Celyad Oncology SA (CLYYF) fair value: what the stock is really worth
As of Sep 25, 2026: fair value of Celyad Oncology SA $0.46, price $0.28, upside +64.3%, quality 56 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
- Fair value above price? Yes
- Good quality? Yes
- Add to watchlist
CO
Thin data
Sep 24, 2026
Thin data
Sep 24, 2026
Celyad Oncology SA
CLYYF · USClearly undervaluedStrong Fair Value upside, but quality is only moderate.
✓Fair value $0.4600 · Strongly undervalued (+64.3%)
!Quality 56/100
!Mixed Growth (revenue 5y +33.2 %/yr)
!Low debt · negative free cash flow
!Moderate moat 56/100
!Evidence only low, so the estimate is less certain
!The models disagree: range $0.3500 to $1.27
Watch Celyad Oncology SA for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.
Watch for free
Pro now: $1 first month
What runs behind every stock
26
valuation models
8 families, DCF to NCAV
37
quality factors
margins, balance sheet, cashflow, debt
6
AI factors
moat, what no ratio measures
2,000+
data points
verified, per stock, median
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range $0.1500 – $9.15 · fair‑value band $0.3500 – $1.27 · the $0.2800 price screens below the $0.4600 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Company profile
Celyad Oncology SA, a biotechnology company, focuses on unlocking the potential of its intellectual property. Its portfolio comprises multiple foundational US patents focused on TCR-deficient T cell compositions, and it broadly covers allogeneic CAR T cell therapies.
Show more
Celyad Oncology SA, a biotechnology company, focuses on unlocking the potential of its intellectual property. Its portfolio comprises multiple foundational US patents focused on TCR-deficient T cell compositions, and it broadly covers allogeneic CAR T cell therapies. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.
Stock analysis
Celyad Oncology SA (CLYYF) currently trades at $0.2800, while our model-based Fair Value estimate is $0.4600, implying the stock looks roughly 39.1% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of $0.9700 per share, and 5 of the 8 models we run sit above the $0.2800 price.
Bear case: the Economic Profit group reads lowest at $0.2100, and 3 of the 8 models stay below the price. Evidence for this calculation is low.
Scenario range: $0.3500 (bear) to $1.27 (bull), the price of $0.2800 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 56/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Celyad Oncology SA reported revenue of €21.0K in FY2025 versus €0 in FY2021. Reported net income was €830K in FY2025.
Key figures
Market cap $13.0M · P/E ratio 14.0 · EPS (TTM) $0.0200 · Net margin 3,952% · Return on equity 56.3% · Return on assets (EBIT) −104% · Operating margin 30,414% · Revenue (TTM) €21.0K.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 43 out of 100 (low confidence).
What moves the price
The share trades about 32% below its 52-week high and 87% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at 64%, CLYYF screens cheaper than that median.
Fair Value models
Bear $0.3500
Fair Value $0.4600
Bull $1.27
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then ($0.0151 per share) are deliberately not added.
Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.
Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
Growth-Adj P/E
$0.6800
$0.9700
$1.26
64
P/E Multiple
$0.3400
$0.4600
$0.5700
63
Graham-Dodd
$0.1400
$0.9900
$1.39
59
All 8 models by family
Earnings-Based
Graham-Dodd
$0.1400
$0.9900
$1.39
59
Lynch FV
$0.5100
$0.7300
$0.9500
57
PEG = 1.0
$0.5100
$0.7300
$0.9500
54
Multiples
P/E Multiple
$0.3400
$0.4600
$0.5700
63
P/B Multiple
$0.2100
$0.2800
$0.3400
55
Asset-Based
NCAV (Graham)
$0.0300
$0.0400
$0.0600
54
Economic Profit
Residual Income
$0.1300
$0.2100
$0.5200
58
Growth Earnings
Growth-Adj P/E
$0.6800
$0.9700
$1.26
64
Notify me when CLYYF reaches fair value
Put CLYYF on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Quality Score breakdown
Overall quality
56/100
Of which business quality 55 · Market factors (momentum, volatility) 36
Profitability
76
Margins and returns on capital today
Quality Growth
49
Are margins and returns improving?
Cashflow
33
Earnings quality: real cash, not paper profit
Fin. Strength
71
Balance sheet, leverage, solvency risk
Investment
100
Disciplined investing over empire-building
Low Volatility
23
Calm price path (market factor)
Momentum
55
Price trend over the last 3–12 months (market factor)
52W Momentum
17
Distance to the 52-week high (market factor)
Net Issuance
0
Share count: buybacks or dilution?
Revenue & earnings trend
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.
52/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−88.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+33.2%
Start year 2020 (pandemic)
Revenue growth 15 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−24.8%
’10
’11
’12
’14
’16
’17
’18
’19
’20
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−339,740.0% (2020) → −34,201.8% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no profitable base year
not computed
Watch CLYYF, get fair value alerts →
Compare Celyad Oncology SA with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 625 stocks
Beats the industry median on 4/7 measures
A mixed picture versus its industry peers.
Valuation Multiplesvs Biotechnology median · lower = cheaper
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Undervalued stocks: US Stocks
- Valuation of the USA market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
None of the checked exposures detected
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $527.67 | $580.44 | +10% |
| Regeneron Pharmaceuticals, Inc REGN | $752.25 | $1,275 | +69% |
| argenx SE ARGX | $959.49 | $918.60 | −4% |
| CSL Limited CSL | A$175.35 | A$192.89 | +10% |
| Samsung Biologics Co 207940 | 1,354,000 KRW | 1,489,400 KRW | +10% |
| BeOne Medicines AG ONC | $360.85 | $280.94 | −22% |
| Alnylam Pharmaceuticals, Inc ALNY | $255.96 | $217.88 | −15% |
| Royalty Pharma plc RPRX | $58.21 | $19.01 | −67% |
| Celltrion, Inc 068270 | 177,400 KRW | 74,519 KRW | −58% |
| WuXi Biologics (Cayman) Inc 2269 | HK$53.00 | HK$58.30 | +10% |
Explore undervalued stocks
More undervalued Healthcare stocks →
All undervalued stocks
TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
🥇 Backtested Best
🏆 Big Names
⭐ Top Rated
💎 Quality on Sale
🚀 Profitable Growth
🧊 Quality Compounders
💵 Dividend Stars
📈 Strong Momentum
📉 Fallen Angels
⚖️ Deeply Undervalued
🔍 Small-Cap Gems
🏰 Moat at a Fair Price
💼 Insider Buying
🎩 Buffett-Style Quality
📚 Peter Lynch GARP
🧮 Greenblatt Magic Formula
🛡️ Graham Defensive
Discover tools
Stock screenerFilter by region, size and sector
Compare toolTwo stocks side by side
Extrinsic Value Calculator…Calculator with industry benchmark
Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
Frequently asked questions
Is Celyad Oncology SA (CLYYF) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $0.4600 versus the last price from Sep 25, 2026 of $0.2800, about +64% upside (undervalued).
What is the fair value of CLYYF?
Our model-based fair value for Celyad Oncology SA is $0.4600 (as of Sep 24, 2026), built from audited fundamentals. Last price (from Sep 25, 2026): $0.2800.
What is the quality score of CLYYF?
Celyad Oncology SA has a Quality Score of 56/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Celyad Oncology SA (CLYYF)?
Our model-based price target is the fair value of $0.4600 (as of Sep 24, 2026) from 8 valuation models. Cautious scenario $0.3500, optimistic scenario $1.27. It is a calculation from audited fundamentals, not an analyst target.
What is the Celyad Oncology SA stock forecast for 2026?
Our models put fair value at $0.4600, about +64% upside versus the last price from Sep 25, 2026 of $0.2800 (undervalued). Cautious scenario $0.3500, optimistic scenario $1.27. The calculation is refreshed regularly with new filings.
What is the revenue of Celyad Oncology SA (CLYYF)?
Celyad Oncology SA reported trailing-twelve-month revenue of about €21.0K (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Celyad Oncology SA (CLYYF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Celyad Oncology SA it is $0.4600 per share (as of Sep 24, 2026), against a price of $0.2800. It is the blended result of 8 valuation models (cash flow, earnings, asset, dividend).
Is Celyad Oncology SA stock overvalued or undervalued in 2026?
As of Sep 24, 2026, CLYYF trades below its calculated fair value: price $0.2800, fair value $0.4600, a gap of about +64% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CLYYF?
No. The price is what the market pays today ($0.2800); the fair value is what the company's own numbers justify ($0.4600). For Celyad Oncology SA the two are $0.1800 per share apart. That gap is exactly why we show both numbers side by side.
How much is Celyad Oncology SA worth?
The market values Celyad Oncology SA at about $13.0M (market capitalisation, as of Sep 24, 2026). Per share that is $0.2800; our models calculate a fair value of $0.4600 per share.
What do the bullish and bearish scenarios say about CLYYF?
Our models span a range for Celyad Oncology SA: cautious scenario $0.3500, base $0.4600, optimistic $1.27 per share (as of Sep 24, 2026, price $0.2800). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of CLYYF?
Celyad Oncology SA trades at a price-to-earnings ratio of 14.0 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $0.4600 is built from several models across several years. Other multiples: P/B 4.6.
How solid is the balance sheet of Celyad Oncology SA (CLYYF)?
Balance-sheet figures for Celyad Oncology SA (as of Sep 24, 2026): return on equity 56.3%. They feed the Quality Score of 56/100, which measures business quality independently of the share price.
How far is CLYYF from its 52-week high?
Celyad Oncology SA trades at $0.2800, about 32% below its 52-week high of $0.4100 and 87% above the low of $0.1500 (as of Sep 25, 2026). Distance from the high says nothing about value: that is what the fair value of $0.4600 is for.
Which stocks are comparable to Celyad Oncology SA?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Celyad Oncology SA stock attractive at the current price?
The data as of Sep 24, 2026: price $0.2800, calculated fair value $0.4600 (+64%), Quality Score 56/100, from 8 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CLYYF calculated?
We run Celyad Oncology SA through 8 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.4600, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Celyad Oncology SA currently trades 39 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Celyad Oncology SA (CLYYF)?
The latest price we hold is from Sep 25, 2026 and stands at $0.2800. Our model-based fair value is $0.4600, about +64% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Celyad Oncology SA right now?
The price is below even our cautious bear case ($0.3500). The market is more pessimistic than our downside scenario. The model range is unusually wide ($0.3500 to $1.27). The outcome hinges heavily on assumptions, so read the point estimate with caution. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (56/100) at a price below fair value, the discount is the argument here, not the business quality.
Key figures of Celyad Oncology SA
How large is the market capitalisation of Celyad Oncology SA (CLYYF)?
The market capitalisation of Celyad Oncology SA is $13.0M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Celyad Oncology SA (CLYYF)?
Earnings per share at Celyad Oncology SA are $0.0200 (price ÷ EPS = P/E 14.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Celyad Oncology SA (CLYYF)?
The net margin of Celyad Oncology SA is 3,952% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Celyad Oncology SA (CLYYF)?
The return on equity (ROE) of Celyad Oncology SA is 56.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Celyad Oncology SA (CLYYF)?
On an EBIT basis the return on assets of Celyad Oncology SA is −104% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Celyad Oncology SA (CLYYF)?
The operating margin of Celyad Oncology SA is 30,414% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Celyad Oncology SA (CLYYF)?
Revenue at Celyad Oncology SA is growing −95.9% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Celyad Oncology SA (CLYYF) generate?
The free cash flow of Celyad Oncology SA is −€6.9M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Celyad Oncology SA (CLYYF) hold?
Celyad Oncology SA holds more cash than debt, €1.7M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Celyad Oncology SA in the live analysis
One click puts Celyad Oncology SA on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.